Functional Assay to Assess T-cell Inhibitory Properties of Myeloid Derived Suppressor Cells (MDSCs) Isolated from the Tumor Microenvironment of Murine Glioma Models

Overview

Journal Methods Enzymol

Specialty Biochemistry

Date 2020 Feb 1

PMID 32000897

Citations 4

Authors

Mahmoud S Alghamri

Neha Kamran

Padma Kadiyala

Pedro Ricardo Lowenstein

Maria Graciela Castro

Affiliations

Soon will be listed here.

Abstract

Despite advances in uncovering the molecular mechanisms that mediate glioma progression and the implementation of novel therapeutic modalities, patients' prognosis remains dismal. This is due to both systemic and local tumor induced immune suppression. We are particularly interested in the role played by infiltrating immunosuppressive myeloid derived suppressor cells (MDSCs) in the glioma tumor microenvironment (TME). This immunosuppressive TME also interferes with the effectiveness of immunotherapies against glioma. Development of multipronged treatment approaches is imperative when aiming to generate a robust anti-glioma immune response. Evaluating the inhibitory potential of MDSCs within the TME is an important aspect for developing effective treatments for glioma. Herein, we discuss methodology to assess the inhibitory effects of MDSCs isolated from the TME using a mouse glioma model.

Citing Articles

Higher cytotoxic activities of CD8 T cells and natural killer cells from peripheral blood of early diagnosed lung cancer patients.

Salem M, Atia I, Elmashad N BMC Immunol. 2023; 24(1):24.

PMID: 37580655 PMC: 10426146. DOI: 10.1186/s12865-023-00553-4.

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas.

Garcia-Fabiani M, Haase S, Banerjee K, McClellan B, Zhu Z, McClellan B bioRxiv. 2023; .

PMID: 37398299 PMC: 10312611. DOI: 10.1101/2023.06.13.544658.

Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations.

Balazs K, Kocsis Z, Agoston P, Jorgo K, Gesztesi L, Farkas G Cancers (Basel). 2022; 14(13).

PMID: 35804830 PMC: 9264868. DOI: 10.3390/cancers14133058.

Macrophages and microglia: the cerberus of glioblastoma.

Buonfiglioli A, Hambardzumyan D Acta Neuropathol Commun. 2021; 9(1):54.

PMID: 33766119 PMC: 7992800. DOI: 10.1186/s40478-021-01156-z.

References

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

Sun H, Zhou X, Xue Y, Wang K, Shen Y, Mao J . Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol. 2012; 18(25):3303-9. PMC: 3391769. DOI: 10.3748/wjg.v18.i25.3303. View

Parker K, Beury D, Ostrand-Rosenberg S . Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015; 128:95-139. PMC: 4662416. DOI: 10.1016/bs.acr.2015.04.002. View

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A . Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111(8):4233-44. DOI: 10.1182/blood-2007-07-099226. View

Calinescu A, Nunez F, Koschmann C, Kolb B, Lowenstein P, Castro M . Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J Vis Exp. 2015; (96). PMC: 4354658. DOI: 10.3791/52443. View

Iclozan C, Antonia S, Chiappori A, Chen D, Gabrilovich D . Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013; 62(5):909-18. PMC: 3662237. DOI: 10.1007/s00262-013-1396-8. View

Romano A, Parrinello N, Vetro C, Forte S, Chiarenza A, Figuera A . Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2014; 168(5):689-700. DOI: 10.1111/bjh.13198. View

Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T . Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013; 62(8):1421-30. PMC: 11029267. DOI: 10.1007/s00262-013-1447-1. View

10.

Angell T, Lechner M, Smith A, Martin S, Groshen S, Maceri D . Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016; 26(3):381-9. PMC: 4790214. DOI: 10.1089/thy.2015.0289. View

11.

Wang L, Chang E, Wong S, Ong S, Chong D, Ling K . Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2012; 190(2):794-804. DOI: 10.4049/jimmunol.1202088. View

12.

Zea A, Rodriguez P, Atkins M, Hernandez C, Signoretti S, Zabaleta J . Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005; 65(8):3044-8. DOI: 10.1158/0008-5472.CAN-04-4505. View

13.

Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q . Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017; 8(24):38378-38388. PMC: 5503539. DOI: 10.18632/oncotarget.16386. View

14.

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

15.

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

16.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

17.

Huang A, Zhang B, Wang B, Zhang F, Fan K, Guo Y . Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013; 62(9):1439-51. PMC: 11028777. DOI: 10.1007/s00262-013-1450-6. View

18.

Jordan K, Amaria R, Ramirez O, Callihan E, Gao D, Borakove M . Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013; 62(11):1711-22. PMC: 4176615. DOI: 10.1007/s00262-013-1475-x. View

19.

Youn J, Nagaraj S, Collazo M, Gabrilovich D . Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008; 181(8):5791-802. PMC: 2575748. DOI: 10.4049/jimmunol.181.8.5791. View

20.

Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala M . Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Mol Ther. 2017; 25(1):232-248. PMC: 5363306. DOI: 10.1016/j.ymthe.2016.10.003. View